Cotinine: Beyond that expected, more than a biomarker of tobacco consumption

Frontiers in Pharmacology

Volumn 3 OCT, Issue , 2012, Pages

  Moran, Valentina Echeverria ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Tampa General Healthcare   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cotinine; Fear; Memory; Nicotine; Tobacco

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; BIOLOGICAL MARKER; CLOZAPINE; COTININE; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; PAROXETINE; PNU 120596; SERTRALINE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; AMNESIA; ARTICLE; DRUG EFFECT; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; INTRACELLULAR SIGNALING; LIGAND BINDING; NEUROPROTECTION; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; PSYCHOPHARMACOLOGY; REINFORCEMENT; SCHIZOPHRENIA; SENSORY GATING; SMOKING HABIT; TOBACCO DEPENDENCE; WORKING MEMORY;

EID: 84870755541     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00173     Document Type: Article

References (133)

1. Ago, Y. (2010). Beneficial effect of galantamine on sensory information-processing deficits. Yakugaku Zasshi 130, 1305-1310.
2. Ago, Y., Koda, K., Takuma, K., and Matsuda, T. (2011). Pharmacological aspects of the acetylcholinesterase inhibitor galantamine. J. Pharmacol. Sci. 116, 6-17
3. AhnAllen, C. G. (2012). The role of the alpha7 nicotinic receptor in cognitive processing of persons with schizophrenia. Curr. Opin. Psychiatry 25, 103-108
4. Araki, H., Suemaru, K., and Gomita, Y. (2002). Neuronal nicotinic receptor and psychiatric disorders: functional and behavioral effects of nicotine. Jpn. I Pharmacol. 88,133-138
5. Aubin, H. J., Rollema, H., Svensson, T. H., and Winterer, G. (2012). Smoking, quitting, and psychiatric disease: a review. Neurosci. Biobehav. Rev. 36, 271-284
6. Balls, E. K. (1962). Early Uses of California Plants. University of California Press
7. Baune, B. T., Miller, R., McAfoose, J., Johnson, M., Quirk, F., and Mitchell, D. (2010). The role of cognitive impairment in general functioning in major depression. Psychiatry Res. 176, 183-189
8. Benowitz, N. L., Kuyt, F., Jacob, P. III, Jones, R. T., and Osman, A. L. (1983). Cotinine disposition and effects. Clin. Pharmacol. Ther. 34, 604-611
9. Benowitz, N. L., and Sharp, D. S. (1989). Inverse relation between serum cotinine concentration and blood pressure in cigarette smokers. Circulation 80,1309-1312
10. Bertrand, D., and Gopalakrishnan, M. (2007). Allosteric modulation of nicotinic acetylcholine receptors. Biochem. Pharmacol. 74, 1155-1163
11. Biedermann, F., and Fleischhacker, W. W. (2011). Emerging drugs for schizophrenia. Expert Opin. Emerg. Drugs 16,271-282
12. Borzelleca, J. F., Bowman, E. R., Mc, K. H. Jr. (1962). Studies on the respiratory and cardiovascular effects of (-)-cotinine.J. Pharmacol. Exp. Ther. 137,313-318
13. Bouton, M. E., Westbrook, R. F., Corcoran, K. A., and Maren, S. (2006). Contextual and temporal modulation of extinction: behavioral and biological mechanisms. Biol. Psychiatry 60,352-360
14. Bowie, C. R., and Harvey, P. D. (2005). Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr. Clin. North Am. 28, 613-633, 626
15. Bowman, E. R., and Mc, K. H. Jr. (1962). Studies on the metabolism of (-)-cotinine in the human. J. Pharmacol. Exp. Ther. 135,306-311
16. Brady, K., Pearlstein, T., Asnis, G. M., Baker, D., Rothbaum, B., Sikes, C. R., et al. (2000). Efficacy and safety of sertraline treatment of posttrau-matic stress disorder: a randomized controlled trial. JAMA 283, 1837-1844
17. Brady, K. T., and Clary, C. M. (2003). Affective and anxiety comorbidity in post-traumatic stress disorder treatment trials of sertraline. Compr. Psychiatry 44, 360-369
18. Braff, D. L., Grillon, C., and Geyer, M. A. (1992). Gating and habituation of the startle reflex in schizophrenic patients. Arch. Gen. Psychiatry 49, 206-215
19. Bramer, S. L., and Kallungal, B. A. (2003). Clinical considerations in study designs that use cotinine as a biomarker. Biomarkers 8, 187-203
20. Breese, C. R., Lee, M. J., Adams, C. E., Sullivan, B., Logel, J., Gillen, K. M., et al. (2000). Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neu-ropsychopharmacology 23, 351-364
21. Briggs, C. A., and McKenna, D. G. (1998). Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonists. Neu-ropharmacology 37, 1095-1102
22. Buccafusco, J. J., Beach, J. W., and Terry, A. V. Jr. (2009). Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J. Pharmacol. Exp. Ther. 328, 364-370
23. Buccafusco, J. J., Shuster, L. C., and Terry, A. V. Jr. (2007). Disconnection between activation and desensitization of autonomic nicotinic receptors by nicotine and cotinine. Neurosci. Lett. 413, 68-71
24. Buccafusco, J. J., and Terry, A. V. Jr. (2003). The potential role of cotinine in the cognitive and neuroprotec-tive actions of nicotine. Life Sci. 72, 2931-2942
25. Buckley, T. C., Holohan, D. R., Moz-ley, S. L., Walsh, K., and Kassel, J. (2007). The effect of nicotine and attention allocation on physiological and self-report measures of induced anxiety in PTSD: a double-blind placebo-controlled trial. Exp. Clin. Psychopharmacol. 15, 154-164
26. Buggia-Prevot, V., Sevalle, J., Rossner, S., and Checler, F. (2008). NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42. J. Biol. Chem. 283, 10037-10047
27. Buhot, M. C., Martin, S., and Segu, L. (2000). Role of serotonin in memory impairment. Ann. Med. 32,210-221
28. Burriss, L., Ayers, E., Ginsberg, J., and Powell, D. A. (2008). Learning and memory impairment in PTSD: relationship to depression. Depress. Anxiety 25, 149-157
29. Caldwell, W. S., Greene, J. M., Byrd, G. D., Chang, K. M., Uhrig, M. S., de Bethizy, J. D., et al. (1992). Characterization of the glucuronide conjugate of cotinine: a previously unidentified major metabolite of nicotine in smokers' urine. Chem. Res. Toxicol. 5, 280-285
30. Chen, X., Garelick, M. G., Wang, H., Lil, V., Athos, J., and Storm, D. R. (2005). PI3 kinase signaling is required for retrieval and extinction of contextual memory. Nat. Neurosci. 8,925-931
31. Ciamei, A., Aversano, M., Cestari, V., and Castellano, C. (2001). Effects of MK-801 and nicotine combinations on memory consolidation in CD1 mice. Psychopharmacology (Berl.) 154,126-130
32. Cohen, H., Kotler, M., Matar, M., and Kaplan, Z. (2000). Normalization of heart rate variability in post-traumatic stress disorder patients following fluoxetine treatment: preliminary results. Isr. Med. Assoc. J. 2, 296-301
33. Corchs, F., Nutt, D. J., Hood, S., and Bernik, M. (2009). Serotonin and sensitivity to trauma-related exposure in selective serotonin reuptake inhibitors-recovered posttraumatic stress disorder. Biol. Psychiatry 66, 17-24
34. Corrigall,W.A.,andCoen,K.M. (1991). Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology (Berl.) 104, 171-176
35. Dalack, G. W., and Meador-Woodruff, J. H. (1996). Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Schizophr. Res. 22, 133-141
36. Dalack, G. W., and Meador-Woodruff, J. H. (1999). Acute feasibility and safety of a smoking reduction strategy for smokers with schizophrenia. Nicotine Tob. Res. 1, 53-57
37. Davidson, J., Pearlstein, T., Londborg, P., Brady, K. T., Rothbaum, B., Bell, J., et al. (2001). Efficacy of sertraline in preventing relapse of post-traumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am. J. Psychiatry 158, 1974-1981
38. De Schepper, P. J., Van Hecken, A., Dae-nens, P., and Van Rossum, J. M. (1987). Kinetics of cotinine after oral and intravenous administration to man. Eur. J. Clin. Pharmacol. 31, 583-588
39. Dodd, S., Brnabic, A. J., Berk, L., Fitzgerald, P. B., de Castella, A. R., Filia, S., et al. (2010). A prospective study of the impact of smoking on outcomes in bipolar and schizoaffective disorder. Compr. Psychiatry 51, 504-509
40. Donato, M. T., Viitala, P., Rodriguez-Antona, C., Lindfors, A., Castell, J. V., Raunio, H., et al. (2000). CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. Drug Metab. Dispos. 28, 1321-1326
41. Echeverria, V., and Zeitlin, R. (2012). Cotinine: a potential new therapeutic agent against Alzheimer's disease. CNS Neurosci. Ther. 18,517-523
42. Echeverria, V., Zeitlin, R., Burgess, S., Patel, S., Barman, A., Thakur, G., et al. (2011). Cotinine Reduces Amyloid-β aggregation and improves memory in Alzheimer's disease mice. J. Alzheimers Dis. 24, 817-835
43. Elzinga, B. M., and Bremner, J. D. (2002). Are the neural substrates of memory the final common pathway in posttraumatic stress disorder (PTSD)? J. Affect. Disord. 70, 1-17
44. Faghih, R., Gfesser, G. A., and Gopalakr-ishnan, M. (2007). Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor. Recent Pat. CNS DrugDiscov. 2, 99-106.
45. Fischer, A., Radulovic, M., Schrick, C., Sananbenesi, F., Godovac-Zimmermann, J., and Radulovic, J. (2007). Hippocampal Mek/Erk signaling mediates extinction of contextual freezing behavior. Neurobiol. Learn. Mem. 87,149-158
46. Freedman, R., Adler, L. E., Bickford, P., Byerley, W., Coon, H., Cullum, C. M., et al. (1994). Schizophrenia and nicotinic receptors. Harv. Rev. Psychiatry 2, 179-192.
47. Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M.,Johnson, L., et al. (2008). Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry 165, 1040-1047
48. Freedman, R., Wetmore, C., Stromberg, I., Leonard, S., and Olson, L. (1993). Alpha-bungarotoxin binding to hippocampal interneurons: immuno-cytochemical characterization and effects on growth factor expression. J. Neurosci. 13, 1965-1975
49. Fuxe, K., Everitt, B. J., and Hokfelt, T. (1979). On the action of nicotine and cotinine on central 5-hydroxytryptamine neurons. Pharmacol Biochem. Behav. 10, 671-677
50. Gately, I. (2003). Tobacco: A Cultural History of How an Exotic Plant Seduced Civilization. Diane
51. Geyer, M. A. (2006). Are cross-species measures of sensorimotor gating useful for the discovery of procogni-tive cotreatments for schizophrenia? Dialogues Clin. Neurosci. 8, 9-16
52. Ghosheh, O., and Hawes, E. M. (2002). N-glucuronidation of nicotine and cotinine in human: formation of cotinine glucuronide in liver microsomes and lack of catalysis by 10 examined UDP-glucuronosyltransferases. Drug Metab. Dispos. 30, 991-996
53. Glynn, S. M., and Sussman, S. (1990). Why patients smoke. Hosp. Community Psychiatry 41, 1027-1028
54. Gray, J. A., and Roth, B. L. (2007). Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr. Bull. 33, 1100-1119
55. Hajos, M., and Rogers, B. N. (2010). Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia. Curr. Pharm. Des. 16, 538-554
56. Hapke, U., Schumann, A., Rumpf, H. J., John, U., Konerding, U., and Meyer, C. (2005). Association of smoking and nicotine dependence with trauma and posttraumatic stress disorder in a general population sample. J. Nerv. Ment. Dis. 193, 843-846
57. Hatsukami, D., Pentel, P. R., Jensen, J., Nelson, D., Allen, S. S., Goldman, A., et al. (1998). Cotinine: effects with and without nicotine. Psychophar-macology (Berl.) 135,141-150
58. Hatsukami, D. K., Grillo, M., Pentel, P. R., Oncken, C., and Bliss, R. (1997). Safety of cotinine in humans: physiologic, subjective, and cognitive effects. Pharmacol Biochem. Behav. 57, 643-650
59. Hatsukami, D. K., Jensen, J., Brauer, L. H., Mooney M., Schulte, S., Sofuoglu, M., et al. (2003). Lack of effect of 5HT3 antagonist in mediating subjective and behavioral responses to cotinine. Pharmacol. Biochem. Behav. 75,1-7
60. Hinkelmann, K., Moritz, S., Botzen-hardt, J., Riedesel, K., Wiedemann, K., Kellner, M., et al. (2009). Cognitive impairment in major depression: association with salivary corti-sol. Biol Psychiatry 66, 879-885
61. Holt, D. J., Lebron-Milad, K., Milad, M. R., Rauch, S. L., Pitman, R. K., Orr, S. P., et al. (2009). Extinction memory is impaired in schizophrenia. Biol. Psychiatry 65,455-463
62. Horner, M. D., and Hamner, M. B. (2002). Neurocognitive functioning in posttraumatic stress disorder. Neuropsychol. Rev. 12, 15-30
63. Hukkanen, J., Jacob, P. III, and Benowitz, N. L. (2006). Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. Clin. Pharmacol Ther. 80, 522-530
64. Izquierdo, I., Cammarota, M., Vianna, M. M., and Bevilaqua, L. R. (2004). The inhibition of acquired fear. Neu-rotox. Res. 6, 175-188
65. Johnsen, G. E., and Asbjornsen, A. E. (2009). Verbal learning and memory impairments in posttraumatic stress disorder: the role of encoding strategies. Psychiatry Res. 165,68-77
66. Karaconji,I.B. (2005). Facts about nicotine toxicity. Arh. Hig. Rada Toksikol. 56,363-371
67. Karam, C. S., Ballon, J. S., Bivens, N. M., Freyberg, Z., Girgis, R. R., Lizardi-Ortiz, J. E., et al. (2012). Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol Sci. 31,381-390
68. Kelly, D. L., McMahon, R. P., Wehring, H. J., Liu, F., Mackowick, K. M., Boggs, D. L., et al. (2011). Cigarette smoking and mortality risk in people with schizophrenia. Schizophr. Bull. 37, 832-838
69. Kim, A. H., Khursigara, G., Sun, X., Franke, T. F., and Chao, M. V. (2001). Akt phosphorylates and negatively regulates apoptosis signal-regulating kina(se 1). Mol Cell. Biol. 21,893-901
70. Kuehl, G. E., and Murphy, S. E. (2003). N-glucuronidation of trans-3'-hydroxycotinine by human liver microsomes. Chem. Res. Toxicol. 16, 1502-1506
71. Lang, U. E., Puls, I., Muller, D. J., Strutz-Seebohm, N., and Gallinat, J. (2007). Molecular mechanisms of schizophrenia. Cell Physiol. Biochem. 20, 687-702
72. Leiser, S. C., Bowlby, M. R., Comery, T. A., and Dunlop, J. (2009). A cog in cognition: how the alpha7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol Ther. 122, 302-311
73. Leonard, S., Adler, L. E., Benhammou, K., Berger, R., Breese, C. R., Drebing, C., et al. (2001). Smoking and mental illness. Pharmacol. Biochem. Behav. 70, 561-570
74. Leonard, S., Breese, C., Adams, C., Benhammou, K., Gault, J., Stevens, K., et al. (2000). Smoking and schizophrenia: abnormal nicotinic receptor expression. Eur. J. Pharmacol. 393,237-242
75. Leonard, S., Gault, J., Adams, C., Breese, C. R., Rollins, Y., Adler, L. E., et al. (1998). Nicotinic receptors, smoking and schizophrenia. Restor. Neurol. Neurosci. 12, 195-201
76. Levin, E. D. (2002). Nicotinic receptor subtypes and cognitive function. J. Neurobiol. 53, 633-640
77. Levin, E. D., Bettegowda, C., Weaver, T., and Christopher, N. C. (1998). Nicotine-dizocilpine interactions and working and reference memory performance of rats in the radialarm maze. Pharmacol. Biochem. Behav. 61, 335-340
78. Lewis, D. F., Dickins, M., Lake, B. G., Eddershaw, P. J., Tarbit, M. H., and Goldfarb, P. S. (1999). Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity. Toxicology 133, 1-33
79. Luck, S. J., and Gold, J. M. (2008). The construct of attention in schizophrenia. Biol Psychiatry 64, 34-39
80. Lyon, E. R. (1999). A review of the effects of nicotine on schizophrenia and antipsychotic medications. Psychiatr. Serv. 50,1346-1350
81. Malaiyandi, V., Goodz, S. D., Sellers, E. M., and Tyndale, R. F. (2006). CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiol Biomarkers Prev. 15, 1812-1819
82. Martenyi, F., Brown, E. B., and Cald-well, C. D. (2007). Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study. J. Clin. Psychopharmacol. 27, 166-170
83. Matthews, A. M., Wilson, V. B., and Mitchell, S. H. (2011). The role of antipsychotics in smoking and smoking cessation. CNS Drugs 25, 299-315
84. McEvoy, J. P., Freudenreich, O., and Wilson, W H. (1999). Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol. Psychiatry 46,125-129
85. McGehee, D. S., and Role, L. W (1995). Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu. Rev. Physiol. 57,521-546
86. Mexal, S., Berger, R., Logel, J., Ross, R. G., Freedman, R., and Leonard, S. (2010). Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers. J. Mol Neurosci. 40, 185-195
87. Money, T. T., Scarr, E., Udawela, M., Gibbons, A. S., Jeon, W. J., Seo, M. S., et al. (2012). Treating schizophrenia: novel targets for the cholinergic system. CNS Neurol Disord. Drug Targets 9, 241-256
88. Nakajima, M., Fukami, T., Yamanaka, H., Higashi, E., Sakai, H., Yoshida, R., et al. (2006). Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin. Pharmacol. Ther. 80, 282-297
89. Nutt, D. J. (2000). The psychobiology of posttraumatic stress disorder. J. Clin. Psychiatry 61(Suppl. 5), 24-29; discussion 30-22
90. Ohno, M., Chang, L., Tseng, W., Oakley, H., Citron, M., Klein, W. L., et al. (2006). Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of B(ACE1). Eur. J. Neurosci. 23, 251-260
91. O'Leary, K., Parameswaran, N., McIn-tosh, J. M., and Quik, M. (2008). Cotinine selectively activates a sub-population of alpha3/alpha6beta2 nicotinic receptors in monkey stria-tum. J. Pharmacol. Exp. Ther. 325, 646-654
92. Olincy, A., and Stevens, K. E. (2007). Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men. Biochem. Phar-macol.74, 1192-1201
93. Peto, R., Lopez, A. D., Boreham, J., Thun, M., Heath, C. Jr., and Doll, R. (1996). Mortality from smoking worldwide. Br.Med. Bull. 52, 12-21
94. Quirk, G. J., and Mueller, D. (2008). Neural mechanisms of extinction learning and retrieval. Neuropsy-chopharmacology 33, 56-72
95. Rabin, R. A., Sacco, K. A., and George, T. P. (2009). Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: effects of smoking status. Schizophr. Res. 114,91-97
96. Riah, O., Courriere, P., Dousset, J. C., Todeschi, N., and Labat, C. (1998). Nicotine is more efficient than cotinine at passing the blood-brain barrier in rats. Cell. Mol Neurobiol. 18, 311-318
97. Riah, O., Dousset, J. C., Bofill-Cardona, E., and Courriere, P. (2000). Isolation and microsequencing of a novel cotinine receptor. Cell. Mol. Neurobiol. 20,653-664
98. Riah, O., Dousset, J. C., Courriere, P., Stigliani, J. L., Baziard-Mouysset, G., and Belahsen, Y. (1999). Evidence that nicotine acetylcholine receptors are not the main targets of cotinine toxicity. Toxicol Lett. 109, 21-29
99. Risner, M. E., Goldberg, S. R., Prada, J. A., and Cone, E. J. (1985). Effects of nicotine, cocaine and some of their metabolites on schedule-controlled responding by beagle dogs and squirrel monkeys. J. Pharmacol Exp. Ther. 234, 113-119
100. Robbins, T. W. (2002). The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacol-ogy (Berl.) 163, 362-380
101. Robinson, E. S., Eagle, D. M., Econo-midou, D., Theobald, D. E., Mar, A. C., Murphy, E. R., et al. (2009). Behavioural characterisation of high impulsivity on the 5-choice serial reaction time task: specific deficits in "waiting" versus "stopping." Behav. Brain Res. 196,310-316
102. Rubboli, F., Court, J. A., Sala, C., Morris, C., Chini, B., Perry, E., et al. (1994a). Distribution of nicotinic receptors in the human hippocampus and thalamus. Eur. J. Neurosci. 6,1596-1604
103. Rubboli, F., Court, J. A., Sala, C., Morris, C., Perry, E., and Clementi, E (1994b). Distribution of neu-ronal nicotinic receptor subunits in human brain. Neurochem. Int. 25, 69-71
104. Sagud, M., Mihaljevic-Peles, A., Muck-Seler, D., Pivac, N., Vuksan-Cusa, B., Brataljenovic, T., et al. (2009). Smoking and schizophrenia. Psychiatr. Danub. 21, 371-375
105. Seillier, A., and Giuffrida, A. (2009). Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK(-801). Behav. Brain Res. 204, 410-415
106. Smith, R. C., Singh, A., Infante, M., Khandat, A., and Kloos, A. (2002). Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 27,479-497
107. Smith, R. C., Warner-Cohen, J., Matute, M., Butler, E., Kelly, E., Vaid-hyanathaswamy, S., et al. (2006). Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology 31, 637-643
108. Steckler, T., and Risbrough, V. (2012). Pharmacological treatment of PTSD - Established and new approaches. Neuropharmacology 62, 617-627
109. Stein, D. J., Ipser, J., and McAnda, N. (2009). Pharmacotherapy of post-traumatic stress disorder: a review of meta-analyses and treatment guidelines. CNSSpectr. 14,25-31
110. Strasser, A. A., Malaiyandi, V., Hoffmann, E., Tyndale, R. F., and Lerman, C. (2007). An association of CYP2A6 genotype and smoking topography. Nicotine Tob. Res. 9, 511-518
111. Suemaru, K., Yasuda, K., Umeda, K., Araki, H., Shibata, K., Choshi, T., et al. (2004). Nicotine blocks apomorphine-induced disruption of prepulse inhibition of the acoustic startle in rats: possible involvement of central nicotinic alpha7 receptors. Br. J. Pharmacol. 142, 843-850
112. Sugaya, K., Giacobini, E., and Chiappinelli, V. A. (1990). Nicotinic acetylcholine receptor subtypes in human frontal cortex: changes in Alzheimer's disease. J. Neurosci. Res. 27, 349-359
113. Swerdlow, N. R., Light, G. A., Cadenhead, K. S., Sprock, J., Hsieh, M. H., and Braff, D. L. (2006). Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch. Gen. Psychiatry 63, 1325-1335
114. Taly, A., Corringer, P. J., Guedin, D., Lestage, P., and Changeux, J. P. (2009). Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat. Rev. DrugDiscov. 8, 733-750
115. Tapia, G., Clarys, D., El Hage, W., Belzung, C., and Isingrini, M. (2007). PTSD psychiatric patients exhibit a deficit in remembering. Memory 15, 145-153
116. Tassaneeyakul, W., Guo, L. Q., Fukuda, K., Ohta, T., and Yamazoe, Y. (2000). Inhibition selectivity of grapefruit juice components on human cytochromes (P450). Arch. Biochem. Biophys. 378, 356-363
117. Terry, A. V. Jr., Buccafusco, J. J., Schade, R. F., Vandenhuerk, L., Callahan, P. M., Beck, W D., et al. (2012). The nicotine metabolite, cotinine, attenuates glutamate (NMDA) antagonist-related effects on the performance of the five choice serial reaction time task (5C-SRTT) in rats. Biochem. Pharmacol. 83, 941-951
118. Terry, A. V. Jr., Buccafusco, J. J., and Wilson, C. (2008). Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav. Brain Res. 195, 30-38
119. Terry, A. V. Jr., Hernandez, C. M., Hohnadel, E. J., Bouchard, K. P., and Buccafusco, J. J. (2005). Cotinine, a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition. CNS Drug Rev. 11,229-252
120. Thorndike, F. P., Wernicke, R., Pearlman, M. Y., and Haaga, D. A. (2006). Nicotine dependence, PTSD symptoms, and depression prone-ness among male and female smokers. Addict Behav. 31,223-231
121. Toyohara, J., and Hashimoto, K. (2010). alpha7 nicotinic receptor agonists: potential therapeutic drugs for treatment of cognitive impairments in schizophrenia and Alzheimer's disease. Open Med. Chem. J. 4, 37-56
122. van Os, J., and Kapur, S. (2009). Schizophrenia. Lancet 374, 635-645
123. Van Snellenberg, J. X. (2009). Working memory and longterm memory deficits in schizophrenia: is there a common substrate? Psychiatry Res. 174, 89-96
124. Veltmeyer, M. D., Clark, C. R., McFarlane, A. C., Moores, K. A., Bryant, R. A., and Gordon, E. (2009). Working memory function in post-traumatic stress disorder: an event-related potential study. Clin. Neuro-physiol. 120, 1096-1106
125. Visoni, S., Meireles, N., Monteiro, L., Rossini, A., and Pinto, L. F. (2008). Different modes of inhibition of mouse Cyp2a5 and rat CYP2A3 by the food-derived 8-methoxypsoralen. Food Chem. Toxicol. 46, 1190-1195
126. von Hausswolff-Juhlin, Y., Bjartveit, M., Lindstrom, E., and Jones, P. (2009). Schizophrenia and physical health problems. Acta Psychiatr. Scand. Suppl. 15-21
127. Weaver, T. L., and Etzel, J. C. (2003). Smoking patterns, symptoms of PTSD and depression: preliminary findings from a sample of severely battered women. Addict. Behav. 28, 1665-1679
128. Woodruff-Pak, D. S., and Gould, T. J. (2002). Neuronal nicotinic acetylcholine receptors: involvement in Alzheimer's disease and schizophrenia. Behav. Cogn. Neurosci. Rev. 1, 5-20.
129. Yakel, J. L. (2012). Nicotinic ACh receptors in the hippocampus: role in excitability and plasticity. Nicotine Tob. Res. [Epub ahead of print]
130. Yamanaka, H., Nakajima, M., Nishimura, K., Yoshida, R., Fukami, T., Katoh, M., et al. (2004). Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. Eur. J. Pharm. Sci. 22, 419-425
131. Yehuda, R., Giller, E. L., Southwick, S. M., Lowy, M. T., and Mason, J. W. (1991). Hypothalamic-pituitary-adrenal dysfunction in posttrau-matic stress disorder. Biol Psychiatry 30,1031-1048
132. Young, G. T., Zwart, R., Walker, A. S., Sher, E., and Millar, N. S. (2008). Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc. Natl. Acad. Sci. U.S.A. 105, 14686-14691
133. Zeitlin, R., Patel, S., Solomon, R., Tran, J., Weeber, E. J., and Echeverria, V. (2012). Cotinine enhances the extinction of contextual fear memory and reduces anxiety after fear conditioning. Behav. Brain Res. 228, 284-293